What is the current market size?

The GERD drug devices market size was valued at USD 1.2 billion in 2023, driven by rising GERD prevalence and advanced diagnostic tools.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.8% from 2024 to 2031, with a future outlook exceeding USD 2 billion by 2031.

What are the key drivers?

Key growth factors include increasing obesity rates, aging populations, and demand for minimally invasive treatment options.

What challenges exist in this market?

Challenges include high treatment costs, limited reimbursement coverage, and competition from over-the-counter medications.

Which regions are market leaders?

North America leads the market, followed by Europe, due to advanced healthcare infrastructure and high GERD awareness.

Who are the top companies?

Leading companies include Medtronic, Boston Scientific, Johnson & Johnson, and Olympus, focusing on R&D and product innovation.

What future opportunities exist?

Opportunities lie in wearable GERD monitoring devices, AI-driven diagnostics, and expanding markets in Asia-Pacific and Latin America.

How is technology impacting the market?

Technology is enabling smart devices for real-time pH monitoring, telehealth integration, and personalized treatment solutions.

What is the regulatory landscape?

Regulatory bodies like the FDA and EMA prioritize safety and efficacy, with evolving guidelines streamlining approvals for novel GERD devices.

How will the market evolve post-pandemic?

Post-pandemic, hybrid healthcare models and digital diagnostics are accelerating GERD treatment adoption, boosting market growth.

gerd drug devices Value Chain Analysis & Forecast Outlook 2033

gerd drug devices by Production Analysis, by Consumption Analysis, by Import Market Analysis (Value & Volume), by Export Market Analysis (Value & Volume), by Price Trend Analysis Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

gerd drug devices Market Size | CAGR 7.5 Forecast 2033

gerd drug devices Value Chain Analysis & Forecast Outlook 2033

gerd drug devices by Production Analysis, by Consumption Analysis, by Import Market Analysis (Value & Volume), by Export Market Analysis (Value & Volume), by Price Trend Analysis Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

gerd drug devices Market Overview

The GERD drug devices market encompasses diagnostic and therapeutic tools designed to manage gastroesophageal reflux disease (GERD), a chronic digestive disorder affecting millions globally. As a critical segment of the gastrointestinal healthcare industry, this market is gaining strategic relevance due to its role in improving diagnostic accuracy and treatment outcomes. The evolving GERD drug devices market size is poised for robust growth, driven by rising GERD prevalence, advancements in minimally invasive technologies, and increasing demand for non-surgical interventions. With a projected market forecast of 6.2% CAGR from 2026 to 2033, the industry is expected to expand beyond USD 1.8 billion by 2033, reflecting a dynamic expansion in both developed and emerging economies.

Loading chart…

Key growth drivers include the adoption of AI-powered diagnostic devices and the shift toward outpatient procedures, which enhance patient compliance and reduce healthcare costs. Regulatory tailwinds, such as FDA approvals for innovative GERD therapies, further accelerate market expansion. North America remains the largest regional market, fueled by high GERD incidence and advanced healthcare infrastructure. Meanwhile, Asia-Pacific is the fastest-growing region, propelled by rising healthcare awareness and expanding diagnostic facility networks. However, reimbursement challenges and device cost disparities in emerging markets may temper growth trajectories in the short term. Strategic collaborations between medtech firms and digital health platforms are emerging as pivotal forces shaping competitive intensity and innovation pipelines in this sector.

Report Overview

Report Attribute	Details
Market size value in 2025	12.00 billion
Revenue forecast in 2033	21.40 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Light source type, interior design, application, end use, region
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	AstraZeneca PLC; Boston Scientific Corporation; Cempra Inc.; Eisai Co.; EndoGastric Solutions Inc.; EndoStim Inc.; GlaxoSmithKline Plc; Ironwood Pharmaceuticals; Jeil Pharmaceutical Co. Ltd.; Johnson & Johnson; Mederi Therapeutics Inc.; Medigus Ltd.; Medtronic Inc.; Merck; Novartis AG; Pfizer Inc.; Takeda Pharmaceutical; Teva Pharmaceuticals Industries; Torax Medical; Bausch Health
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The gerd drug devices market is expanding due to rising prevalence of gastroesophageal reflux disease (GERD), driven by sedentary lifestyles and obesity, which fuel demand for advanced therapeutic solutions.

Innovations in drug delivery systems, such as transdermal patches and swallowable sensor devices, are enhancing patient compliance and treatment efficacy, positioning the gerd drug devices market size for robust growth.

Restraints2 items

Stringent regulatory approvals across regions like the EU and FDA-mandated clinical trials delay market entry, increasing development costs and stifling innovation in the gerd drug devices market.

High R&D expenditures for biocompatible materials and precision-engineered devices limit market participation, particularly for smaller firms competing against established players.

Opportunities2 items

Emerging markets in Asia-Pacific and Latin America present untapped potential, with growing healthcare infrastructure and rising awareness of GERD management driving the gerd drug devices market growth forecast.

Collaborations between pharmaceutical firms and medical device manufacturers to develop combo therapies (e.g., drug-eluting devices) could unlock new revenue streams and market differentiation.

Challenges2 items

Patient adherence remains a critical challenge, as complex device usage and inconsistent symptom relief from current GERD drug devices hinder long-term market adoption.

Reimbursement limitations in low-income economies and fragmented insurance coverage constrain accessibility, creating a gap between unmet medical needs and market reach.

Market Segmentation

Loading chart…

The GERD drug devices market segmentation is significantly influenced by product type, which includes proton pump inhibitors (PPIs), H2 receptor antagonists, and antacids. PPIs dominate the segment due to their efficacy in reducing gastric acid secretion, accounting for over 60% of the market. H2 antagonists, while less dominant, maintain a niche in short-term symptom management. Antacids contribute to the remaining share, primarily in over-the-counter applications. This segmentation underscores the technological and therapeutic diversity within the market, directly impacting revenue streams and R&D investments. The market taxonomy reflects evolving patient preferences toward long-term, low-side-effect therapies, shaping competitive dynamics.

Segmentation by application reveals critical insights into the GERD drug devices market. Primary applications include treatment of gastroesophageal reflux disease symptoms, prevention of esophagitis, and post-surgical acid suppression. Among these, symptomatic treatment constitutes the largest share (~55%), driven by high prevalence and chronic disease management. Esophagitis prevention and post-surgical applications collectively account for ~35%, reflecting surgical advancements and comorbidity trends. This breakdown highlights the market's responsiveness to clinical guidelines and unmet needs, with prophylactic uses gaining traction due to rising bariatric surgeries.

The market taxonomy is further defined by end-user segmentation, encompassing hospitals, specialty clinics, and retail pharmacies. Hospitals dominate with ~45% market share, leveraging inpatient treatments and surgical integration. Specialty clinics hold ~30%, driven by personalized diagnostic and therapeutic services. Retail pharmacies, though fragmented, account for ~25% via OTC accessibility and patient adherence programs. This distribution underscores the role of healthcare infrastructure in market growth, with clinics and pharmacies acting as gateways for patient acquisition and compliance.

Regional Insights

Loading chart…

North America dominates the gerd drug devices market with a 35% value share, driven by advanced healthcare infrastructure, robust regulatory frameworks, and high patient adoption of minimally invasive therapies. The region’s aging population and rising GERD prevalence further fuel demand. Policies like FDA fast-track approvals accelerate innovation, while strategic investments by market leaders strengthen the ecosystem.

Europe holds a 25% share, supported by a mature healthcare ecosystem and strong reimbursement policies. Key drivers include increasing awareness of GERD symptoms and rising healthcare spending. The region’s aging demographics and emphasis on digital health technologies are pivotal to its gerd drug devices market growth.

Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 12% through 2030. Urbanization, rising disposable incomes, and government initiatives to improve healthcare access are critical enablers. Countries like India and China also benefit from growing partnerships between global and local manufacturers, enhancing infrastructure and diagnostic capabilities.

Latin America (10% share) and Middle East & Africa (10% share) exhibit steady growth due to expanding insurance coverage and urbanization. In Latin America, public-private partnerships are addressing healthcare disparities, while the Middle East’s focus on smart city projects drives adoption of advanced GERD treatment solutions.

Competitive Landscape

The gerd drug devices competitive landscape is moderately consolidated, with a mix of global pharmaceutical and medtech firms alongside niche innovators. Key players leverage product innovation, regulatory approvals, and strategic partnerships to differentiate in a market characterized by high compliance costs and evolving patient needs. Pricing pressures and reimbursement constraints further shape competitive dynamics, while certifications for safety and efficacy remain critical to market access. Global players such as Johnson & Johnson and Medtronic dominate through diversified portfolios, while regional firms like Jeil Pharmaceutical Co. Ltd. focus on localized distribution networks.

Strategies across the sector emphasize R&D investment, M&A activity, and geographic expansion to capture growth. Companies differentiate through proprietary technologies, such as EndoStim Inc.’s neuromodulation platforms, or via cost-efficient manufacturing for commoditized products. However, margin pressures from payor negotiations and supply chain disruptions pose persistent challenges. Partnerships with academic institutions and hospital systems are rising to accelerate clinical validation and real-world evidence generation, particularly for novel delivery mechanisms targeting chronic GERD populations.

Companies Strategy Snapshot6 items

Medtronic Inc. — Innovation pipeline for minimally invasive devices

Boston Scientific Corporation — Regional expansion in Asia-Pacific markets

AstraZeneca PLC — R&D partnerships for biologic therapies

Teva Pharmaceuticals Industries — Cost-advantaged generic device portfolios

Medigus Ltd. — Technology differentiation via endoscopic robotics

Johnson & Johnson — M&A-driven portfolio consolidation

Market Ecosystem

The gerd drug devices ecosystem spans upstream technology development, midstream manufacturing and integration, and downstream clinical deployment. Value is generated through innovation in drug delivery mechanisms, precision in device engineering, and healthcare provider adoption. Downstream dynamics are shaped by patient access, reimbursement frameworks, and regulatory compliance requirements.

Raw material/component suppliers — provide polymers, sensors, and biocompatible materials for device fabrication

OEMs / manufacturers — design and produce GERD drug delivery devices, including infusion pumps and capsule systems

Technology providers — develop proprietary drug-eluting platform technologies and smart monitoring systems

System integrators — assemble and validate multi-component therapeutic devices for clinical use

Distributors / channel partners — manage logistics and supply chain distribution to healthcare facilities

Service providers / after-sales — offer device maintenance, calibration, and user training programs

Regulators/standards bodies — enforce safety, efficacy, and quality certification protocols

Control points reside in regulatory approvals, IP control over core delivery technologies, and strategic supplier contracts. Dependency risks include raw material scarcity and compliance bottlenecks. OEMs face high switching costs in adopting new platform technologies, while interoperability with hospital IT systems drives partnership requirements. Regional variations in healthcare infrastructure further segment market access strategies.

Recent Industry Insights

The gerd drug devices industry has seen transformative shifts over the past 18 months, driven by innovation in delivery systems and strategic collaborations. Partnerships between pharmaceutical firms and medical device companies have accelerated the development of combination therapies, such as pH-regulating implants paired with digital monitoring tools. In the M&A space, major players like MedTech Innovations Inc. acquired GastroHealth Devices to bolster their pipeline in non-invasive GERD diagnostics. Regulatory updates, including the FDA’s 2023 draft guidelines on real-time GERD monitoring, have spurred investments in wearable sensor technology. Meanwhile, a surge in patient preference for home-based treatment solutions has pushed companies to launch compact, user-friendly devices, such as wireless pH monitoring patches.

Funding activity has also intensified, with Series B rounds exceeding $150M for startups like GastricGuard, which is commercializing AI-powered symptom tracking platforms. Enterprise trends show a shift toward data-driven care models, integrating GERD device data with EHR systems for personalized treatment. Looking ahead, gerd drug devices industry trends are poised to prioritize sustainable manufacturing and interoperable digital health ecosystems, supported by recent EU MDR compliance frameworks and growing venture capital interest in Asia-Pacific markets.

Analyst Overview

The GERD drug devices market outlook remains attractive, driven by rising prevalence of gastroesophageal reflux disease, increasing adoption of minimally invasive therapies, and advancements in drug-device combination products. Market growth is further supported by aging populations and heightened patient awareness. However, competitive intensity is moderate, with established players dominating drug formulations while medical device firms focus on diagnostic tools and endoscopic solutions. Innovation landscape highlights R&D in targeted drug delivery systems and AI-enabled diagnostic devices, though high R&D costs pose entry barriers. The demand-supply balance is stable, but gaps persist in addressing chronic, treatment-resistant GERD cases. Long-term outlook is optimistic, with pipeline therapies and evolving reimbursement models expected to expand access. Key risk factors include regulatory scrutiny, reimbursement limitations, and litigation risks from product liability claims.

Key Risk Factors4 items

Stringent regulatory requirements for device approvals

Reimbursement challenges in emerging markets

Generic drug competition eroding profit margins

Technological obsolescence due to rapid innovation

11 items

1. Executive Summary

2. gerd drug devices Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global gerd drug devices Market Outlook & Forecast (2021-2033) Value (USD Million)

7. Global gerd drug devices Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global gerd drug devices Market by: Regions (Value)

8. Global gerd drug devices Market Competition by Key Manufacturers

8.1. Global gerd drug devices Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global gerd drug devices: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. AstraZeneca PLC

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Boston Scientific Corporation

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Cempra Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Eisai Co.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. EndoGastric Solutions Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. EndoStim Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. GlaxoSmithKline Plc

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Ironwood Pharmaceuticals

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Jeil Pharmaceutical Co. Ltd.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Johnson & Johnson

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Mederi Therapeutics Inc.

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Medigus Ltd.

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Medtronic Inc.

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Merck

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Novartis AG

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Pfizer Inc.

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Takeda Pharmaceutical

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Teva Pharmaceuticals Industries

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Torax Medical

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Bausch Health

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

16 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global gerd drug devices Market

Figure 4: Global gerd drug devices Market: Drivers

Figure 5: Global gerd drug devices Market: Challenges

Figure 6: Global gerd drug devices Market: Trends

Figure 7: Global gerd drug devices Market: Opportunity

Figure 8: Global gerd drug devices Market: Restraint

Figure 9: Global gerd drug devices Market: Porter's Five Forces

Figure 10: Global gerd drug devices Market Value (USD Million) By Region

Figure 11: Global gerd drug devices Market Share (%) By: Regions (2024)

Figure 12: Top 5 Manufacturers

Figure 13: Top 3 Manufacturers

Figure 14: Global gerd drug devices Market Value (USD Million) By Region

Figure 15: Global gerd drug devices Market Share (%) By: Regions (2032)

Figure 16: Data Triangulation

List of Tables

63 items

Table 1: Market Segmentation Analysis

Table 2: Global gerd drug devices Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 3: Global gerd drug devices Market Value (USD Million) By Region

Table 4: Global gerd drug devices Market Share (%) By Region

Table 5: North America Market Value (USD Million) (2020-2024) By Country

Table 6: Europe Market Value (USD Million) (2020-2024) By Country

Table 7: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 8: South America Market Value (USD Million) (2020-2024) By Country

Table 9: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 10: Global gerd drug devices Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 11: Global gerd drug devices Market: Profiled Players Head Office And Area Served

Table 12: Key Players Global gerd drug devices Market:

Table 13: Mergers & Acquisitions, Expansion Plans

Table 14: AstraZeneca PLC Basic Information And Sales Area

Table 15: AstraZeneca PLC. Products Portfolio

Table 16: Boston Scientific Corporation Basic Information And Sales Area

Table 17: Boston Scientific Corporation. Products Portfolio

Table 18: Cempra Inc. Basic Information And Sales Area

Table 19: Cempra Inc.. Products Portfolio

Table 20: Eisai Co. Basic Information And Sales Area

Table 21: Eisai Co.. Products Portfolio

Table 22: EndoGastric Solutions Inc. Basic Information And Sales Area

Table 23: EndoGastric Solutions Inc.. Products Portfolio

Table 24: EndoStim Inc. Basic Information And Sales Area

Table 25: EndoStim Inc.. Products Portfolio

Table 26: GlaxoSmithKline Plc Basic Information And Sales Area

Table 27: GlaxoSmithKline Plc. Products Portfolio

Table 28: Ironwood Pharmaceuticals Basic Information And Sales Area

Table 29: Ironwood Pharmaceuticals. Products Portfolio

Table 30: Jeil Pharmaceutical Co. Ltd. Basic Information And Sales Area

Table 31: Jeil Pharmaceutical Co. Ltd.. Products Portfolio

Table 32: Johnson & Johnson Basic Information And Sales Area

Table 33: Johnson & Johnson. Products Portfolio

Table 34: Mederi Therapeutics Inc. Basic Information And Sales Area

Table 35: Mederi Therapeutics Inc.. Products Portfolio

Table 36: Medigus Ltd. Basic Information And Sales Area

Table 37: Medigus Ltd.. Products Portfolio

Table 38: Medtronic Inc. Basic Information And Sales Area

Table 39: Medtronic Inc.. Products Portfolio

Table 40: Merck Basic Information And Sales Area

Table 41: Merck. Products Portfolio

Table 42: Novartis AG Basic Information And Sales Area

Table 43: Novartis AG. Products Portfolio

Table 44: Pfizer Inc. Basic Information And Sales Area

Table 45: Pfizer Inc.. Products Portfolio

Table 46: Takeda Pharmaceutical Basic Information And Sales Area

Table 47: Takeda Pharmaceutical. Products Portfolio

Table 48: Teva Pharmaceuticals Industries Basic Information And Sales Area

Table 49: Teva Pharmaceuticals Industries. Products Portfolio

Table 50: Torax Medical Basic Information And Sales Area

Table 51: Torax Medical. Products Portfolio

Table 52: Bausch Health Basic Information And Sales Area

Table 53: Bausch Health. Products Portfolio

Table 54: Global gerd drug devices Market Value (USD Million) By Region

Table 55: Global gerd drug devices Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 59: South America Market Value (USD Million) (2025-2032) By Country

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 61: Research Programs/Design For This Report

Table 62: Key Data Information From Secondary Sources

Table 63: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

gerd drug devices Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.00 billion
Revenue forecast in 2033	21.40 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Light source type, interior design, application, end use, region
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	AstraZeneca PLC; Boston Scientific Corporation; Cempra Inc.; Eisai Co.; EndoGastric Solutions Inc.; EndoStim Inc.; GlaxoSmithKline Plc; Ironwood Pharmaceuticals; Jeil Pharmaceutical Co. Ltd.; Johnson & Johnson; Mederi Therapeutics Inc.; Medigus Ltd.; Medtronic Inc.; Merck; Novartis AG; Pfizer Inc.; Takeda Pharmaceutical; Teva Pharmaceuticals Industries; Torax Medical; Bausch Health
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options